



(11) **EP 2 582 727 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**19.04.2017 Bulletin 2017/16**

(45) Date of publication and mention  
of the grant of the patent:  
**19.10.2016 Bulletin 2016/42**

(21) Application number: **11796394.2**

(22) Date of filing: **15.06.2011**

(51) Int Cl.:  
**A61K 39/00** <sup>(2006.01)</sup> **C07K 16/18** <sup>(2006.01)</sup>  
**C07K 16/30** <sup>(2006.01)</sup> **G01N 33/574** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/US2011/040580**

(87) International publication number:  
**WO 2011/159835 (22.12.2011 Gazette 2011/51)**

(54) **ANTIBODIES TO ENDOPLASMIN AND THEIR USE**

ANTIKÖRPER ZU ENDOPLASMIN UND DEREN VERWENDUNG

ANTICORPS DIRIGÉS CONTRE L'ENDOPLASMINE ET LEUR UTILISATION

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **16.06.2010 US 355516 P**

(43) Date of publication of application:  
**24.04.2013 Bulletin 2013/17**

(60) Divisional application:  
**16187573.7 / 3 135 692**

(73) Proprietor: **University of Pittsburgh- Of the**  
**Commonwealth**  
**System of Higher Education**  
**Pittsburgh, PA 15260 (US)**

(72) Inventors:  
• **FERRONE, Soldano**  
**Pittsburgh, PA 15217 (US)**  
• **WANG, Xinhui**  
**Pittsburgh, PA 15238 (US)**

- **CONRAD, Thomas, P.**  
**Reston, VA 20191 (US)**
- **FAVOINO, Elvira**  
**I-70010 Casamassima Ba (IT)**
- **HOOD, Brian**  
**Reston, VA 20191 (US)**

(74) Representative: **Gowshall, Jonathan Vallance**  
**Forresters**  
**Skygarden**  
**Erika-Mann-Strasse 11**  
**80636 München (DE)**

(56) References cited:  
**WO-A1-2004/087205 WO-A1-2009/113074**  
**WO-A1-2012/075324 WO-A2-2006/120230**  
**US-A1- 2004 001 789**

- **ARNOLD-SCHILD D. ET AL.: 'One-Step**  
**Single-Chain Fv Recombinant Antibody- based**  
**Purification of gp96 for Vaccine Development'**  
**CANCER RESEARCH vol. 60, 01 August 2000,**  
**pages 4175 - 4178, XP002175252**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).